ACTRN12613000510741招募中未知
Open-label exploratory study of the biological activity of an Australian native food, Davidson Plum, in healthy Australian adults.
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •Aged 18 – 60 years
- •Healthy (no current acute or chronic disease)
- •Individuals willing to comply with the study protocols
- •Individuals willing to have blood taken 2 times during the study
排除标准
- •Individuals with current acute or chronic diseases
- •Individuals with Type I diabetes or Type II diabetes
- •Individuals taking anti-depressants/ anxiolytic medications (multiple drugs/started in the last 6 mths)
- •Individuals taking Warfarin or other anti-coagulant medication, except low dose aspirin (less than or equal to 100mg)
- •Individuals known to have poor venous access
- •Liver function tests greater than 3 times the upper limit of normal at baseline
- •Use of corticosteroids (intra-articular or systemic) within 4 weeks prior to baseline
- •Individuals unwilling to cease taking vitamin/mineral supplements or other complementary medicines 2-4 weeks prior to commencement (washout phase).
- •Recent history of alcohol or substance abuse; >30 std drinks per week
- •Females who are lactating, pregnant or planning to become pregnant (need to be willing to use contraception across course of the trial)
- •Participants who have participated in another clinical trial in the last 30 days
- •Any other condition which needs to be clarified by the Study Coordinators
- •Inability or unwillingness of participant or legally acceptable representative to give written informed consent
研究者
相似试验
已完成
2 期
Study In Rheumatoid ArthritisCTRI/2021/10/037469Mandsaur Institute Of Ayurveda Education And Research60
进行中（未招募）
不适用
An open-label study to investigate the pharmacodynamics of a repeat dose regimen of bevacizumab (10mg/kg q2w) and escalating repeat doses of pazopanib in renal cell carcinomaMetastatic Renal Cell CarcinomaMedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaEUCTR2008-005053-38-GBGlaxoSmithKline Research & Development Ltd.12
已完成
1 期
Admiral: a study of the safety of multiple increasing doses of STK-001 in children and adolescents with Dravet syndromeDravet syndromeNervous System DiseasesEpilepsyISRCTN99651026Stoke Therapeutics, Inc19
招募中
3 期
A safety and efficacy study of GWP42003-P oral solution as adjunctive treatment for Japanese children and adults with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complexennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complexJPRN-jRCT2031220041Yamamoto Tomoyuki84
招募中
2 期
A study to investigate the safety and feasibility of delivering MDMA-assisted psychotherapy to patients with posttraumatic stress disorderPosttraumatic Stress DisorderMental Health - Other mental health disordersACTRN12623000838617Emyria Ltd5